Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Predicting Coronary Angioplasty Benefits

Coronary angioplasty or percutaneous coronary intervention (PCI) reduces angina and improves quality of life in patients with stable ischemic cardiomyopathy, though the ORBITA study has shed new light on this. Meanwhile, we will assume this is indeed the case, until new studies either confirm or refute the above mentioned, controversial study.

Mortalidad y volumen de angioplastias de un centro ¿Tienen relación?Either way, it is not clear whether PCI improves quality of life per se, or if, on the contrary, this depends on other patient-related factors.

 

To answer this question, the authors created a model to predict angina and quality of life at one year after PCI and optical medical therapy (OMT).

 

The prediction model was developed using data from 2287 stable patients from the COURAGE study randomized to PCI + OMT vs. OMT alone.


Read also: Can We Discontinue Betablockers after AMI?


Even though most patients improved regardless received treatment, they observed a marked variability in Seattle’s Angina Questionnaire scores at one year after randomization.

 

PCI presents superior improvement (around 2 points) in the Angina Questionnaire scores vs. OMT alone, which is not affected by the diverse patient baseline characteristics.

The ratio of angina free patients or with good/excellent physical activity or quality of life at one year was 57%, 58% and 66% for the PCI group + OMT, and 50%, 55% and 59% for the OMT group respectively.


Read also: Less Bivalirudin and Minimal Use of Ultrasound for Puncture Is the Worldwide Trend in Transradial Access.


Despite characteristics such as baseline symptoms, age, or diabetes were relevant in predicting symptoms, the most important factor was the magnitude of myocardium subtended by narrowed coronary arteries. The model had a modest to good capacity to discriminate, with excellent calibration.

 

Conclusion

The health status outcomes of stable ischemic heart disease patients treated by OMT+PCI versus OMT alone can be predicted with modest accuracy. Angina and quality of life at 1 year is improved by PCI but is more strongly associated with other patient characteristics rather than PCI per se.

 

Original title: Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease. Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).

Reference: Zugui Zhang et al. Circ Cardiovasc Qual Outcomes. 2018;11:e003971.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...